Two decades of gastrointestinal stromal tumor management with first-line treatment: A case report

Last Updated: Thursday, January 23, 2025

In this case study, a man in his forties with a jejunal GIST was treated with imatinib. After initial surgery and recurrence, he received imatinib therapy, stopped, and restarted due to further recurrence. He has been on imatinib with good tolerance until March 2024, highlighting the drug's long-term potential.

Cureus

NPJ Precision Oncology

KIT mutation-NTRK fusion oncogenic driver switch: A novel mechanism of acquired imatinib resistance in GIST

Case Reports in Oncological Medicine

Pelvic gastrointestinal stromal tumor (GIST) mimicking ovarian cancer in a kidney-liver transplant recipient under chronic immunosuppression

Updates in Surgery

Laparoscopic resection for gastric gastrointestinal stromal tumor at the esophagogastric junction: Feasibility and long-term results

Life

Nationwide multicenter study of advanced endoscopic resection and malignant risk model for gastric myogenic tumors (GASTRO Trial)

Digestive Endoscopy

Endoscopic diagnosis of gastric subepithelial lesions < 20 mm: Current strategies and emerging solutions

Experimental Oncology

Diagnosis and surgical treatment of gastrointestinal stromal tumors of the stomach using minimally invasive technologies

International Journal of Surgical Pathology

Sporadic multiple gastrointestinal stromal tumors with distinct KIT and PDGFRA mutations in two separate tumors: A case report and literature review

Journal of Cancer Research and Therapeutics

A rare entity of esophageal gastrointestinal stromal tumor with literature review

World Journal of Gastrointestinal Oncology

FGFR2 fusions as novel oncogenic drivers in gastrointestinal stromal tumors: Two case reports and review of literature

Journal of Cellular and Molecular Medicine

The mechanisms of imatinib resistance in gastrointestinal stromal tumours: Theoretical basis and therapeutic aspect

Gastrointestinal Stromal Tumor Resource Center